mRNA vaccine reduces melanoma recurrence risk by over 40 percent

Phase III trial results show that a personalized mRNA vaccine, tailored to an individual patient's tumor, reduces melanoma recurrence risk by over 40 percent. This is further evidence of mRNA technology's effectiveness in cancer treatment, extending beyond COVID-19 use. The vaccine is created individually based on each patient's tumor profile.